Breaking News Instant updates and real-time market news.

WTW

Weight Watchers

$79.47

3.11 (4.07%)

, SYX

Systemax

$36.55

-0.57 (-1.54%)

10:20
08/29/18
08/29
10:20
08/29/18
10:20

On The Fly: Top five analyst initiations

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Weight Watchers (WTW) initiated with an Outperform at Oppenheimer. 2. Systemax (SYX) initiated with a Market Perform at William Blair. 3. Broadridge (BR) initiated with a Buy at SunTrust. 4. Mercury General (MCY) initiated with an Outperform at Keefe Bruyette. 5. Immune Design (IMDZ) initiated with a Buy at H.C. Wainwright. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

WTW

Weight Watchers

$79.47

3.11 (4.07%)

SYX

Systemax

$36.55

-0.57 (-1.54%)

BR

Broadridge

$134.39

1.33 (1.00%)

MCY

Mercury General

$53.21

0.91 (1.74%)

IMDZ

Immune Design

$3.55

0.125 (3.65%)

  • 05

    Sep

  • 27

    Sep

WTW Weight Watchers
$79.47

3.11 (4.07%)

08/28/18
OPCO
08/28/18
INITIATION
Target $98
OPCO
Outperform
Weight Watchers initiated with an Outperform at Oppenheimer
Oppenheimer analyst Brian Nagel started Weight Watchers with an Outperform rating and $98 price target. A "significant transformation" is taking place at Weight Watchers under new CEO Mindy Grossman, Nagel tells investors in a research note. The analyst sees potential for a "sustained, stronger and higher margin growth trajectory" and believes the recent pullback in the shares is related to technicals, not fundamentals. He thinks the stock offers 30% upside.
08/27/18
DADA
08/27/18
NO CHANGE
Target $143
DADA
Buy
Weight Watchers valuation 'very attractive', says DA Davidson
DA Davidson analyst Linda Bolton Weiser kept her Buy rating and $143 price target on Weight Watchers after her meeting with its CEO Mindy Grossman at the company's WW GOOD Festival in New York, which she states was the biggest of its 6 festivals. Weiser cites Grossman touting the event's "healthy habits" booths as potential areas of expansion and believes that "skin, sleep, and hydration booths seemed like particularly relevant products" areas. With Weight Watchers stock down 27% from its June highs, the analyst further notes that its valuation is "very attractive", trading at 15.7-times her expected forward earnings, while the company's 2018 sales growth trend of 19% is above its 15%-16% annualized 3-year target.
08/07/18
JPMS
08/07/18
NO CHANGE
Target $120
JPMS
Overweight
Weight Watchers price target raised to $120 from $105 at JPMorgan
JPMorgan analyst Christina Brathwaite raised his price target for Weight Watchers International to $120 following the company's Q2 results. Guidance was raised on better than expected constant currency revenue growth, which fully offset a currency headwind in the second half of the year, as well as better than expected gross margins, Brathwaite tells investors in a research note. The analyst sees "significant potential" for earnings leverage in 2018 and keeps an Overweight rating on Weight Watchers.
08/07/18
RILY
08/07/18
NO CHANGE
Target $113
RILY
Buy
Weight Watchers price target raised to $113 from $103 at B. Riley FBR
B. Riley FBR analyst Kara Anderson raised her price target for Weight Watchers to $113 citing increased margin expectations following the company's Q2 results. The analyst keeps a Buy rating on the shares.
SYX Systemax
$36.55

-0.57 (-1.54%)

08/29/18
08/29/18
INITIATION

Market Perform
William Blair starts Systemax at Market Perform on 'full valuation'
As previously reported, William Blair analyst Ryan Merkel earlier today initiated coverage of Systemax (SYX) with a Market Perform rating. Systemax is well positioned to achieve its near-term target of 10% EBITDA margins and sales of $1B, Merkel tells investors in a research note. The analyst, however, views the company's current valuation as "full" and thinks the industrial cycle is potentially nearing its peak.
08/29/18
WBLR
08/29/18
INITIATION
WBLR
Market Perform
Systemax initiated with a Market Perform at William Blair
William Blair analyst Ryan Merkel started Systemax with a Market Perform rating.
08/22/18
08/22/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. SIDOTI UPGRADES SYSTEMAX TO BUY: Sidoti analyst Anthony Lebiedzinski upgraded Systemax (SYX) to Buy from Neutral. The analyst said the recent selloff in shares is overdone and maintained a $45 price target. Systemax shares are up 10.2% in morning trading. PIPER CUTS STARBUCKS TO NEUTRAL: Piper Jaffray analyst Nicole Miller Regan downgraded Starbucks (SBUX) last night to Neutral from Overweight and lowered her price target for the shares to $53 from $60. The motivation for the downgrade was another month of U.S. checks that suggested a lack of comp performance, Miller Regan said. The analyst believes shares of Starbucks will be "range bound at best" until U.S. trends improve. She sees issues around "inconsistent results, credibility of guidance, and management transitions." Miller Regan thinks the stock has "modest downside risk." MKM BOOSTS NETFLIX TARGET TO $395: MKM Partners analyst Rob Sanderson raised his price target for Netflix (NFLX) to $395 from $390 and kept a Buy rating on the shares after updating his estimates. The analyst said his "previous caution" on the shares is "now reversed" following the recent stock price correction. His subscriber ramp expectations are "somewhat lower" in the near-to-medium term but remain unchanged in the long-term. Netflix will approach full penetration of the U.S. over time, growing to 90M subscribers by 2025, Sanderson said. He continues to see over $40 per share in earnings power at 90M U.S. and 300M international subscribers, which he projected in the 2025 timeframe. Expectations for Netflix became "somewhat elevated, but have been appropriately moderated," Sanderson contended. He called the stock a "must-own for growth managers." BAIRD SAYS STAR WARS LICENSE ADDS VISIBILITY FOR ZYNGA: Baird analyst Colin Sebastian believes the Star Wars license announced adds some visibility to Zynga's (ZNGA) out-year growth targets. The new Disney (DIS) license is a positive development for Zynga for the longer-term given the popularity of the Star Wars franchise, Sebastian said. That said, he does not expect a material contribution from new titles until 2020. As such, Sebastian kept a Neutral rating on Zynga shares. Znga shares are up 7.6% in late morning trading. PIPER SAYS FACEBOOK USERS 'UNFAZED' BY ISSUES: Piper Jaffray analyst Michael Olson said his firm's survey of 1,300 Facebook (FB) and Instagram users leaves him confident that "most are unfazed by the negative news flow." The analyst kept an Overweight rating on Facebook shares with a $200 price target.
08/22/18
08/22/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1.Systemax (SYX) upgraded to Buy from Neutral at Sidoti with analyst Anthony Lebiedzinski saying the recent selloff in shares is overdone. 2. Itron (ITRI) upgraded to Buy from Hold at Argus with analyst John Eade saying while the stock price has trended in a bearish pattern until recently and latest earnings have underperformed, its bookings appear to be in "solid shape." 3. Landstar System (LSTR) upgraded to Outperform from Market Perform at Wells Fargo with analyst Casey Deak saying he has become more positive on the brokerage space moving into 2019. 4. YRC Worldwide (YRCW) upgraded to Buy from Hold at Deutsche Bank with analyst Amit Mehrotra saying he believes continued pricing and yield improvement, renewal of YRC's aging fleet and opportunities to improve labor flexibility and driver productivity will drive better equity value. 5. MercadoLibre (MELI) upgraded to Buy from Hold at Stifel with analyst Scott Devitt saying he believes Q2 was a "transitional" quarter and that management reacted quickly to the Correios price increase by finding the right balance between growth and profitability to position the company well for the long term. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
BR Broadridge
$134.39

1.33 (1.00%)

07/17/18
WOLF
07/17/18
INITIATION
Target $128
WOLF
Peer Perform
Broadridge initiated with a Peer Perform at Wolfe Research
Wolfe Research analyst Darrin Peller started Broadridge with a Peer Perform rating and $128 price target.Target $128.
11/09/17
DADA
11/09/17
NO CHANGE
Target $86
DADA
Neutral
Broadridge price target raised to $86 from $80 at DA Davidson
DA Davidson analyst Peter Heckmann raised his price target on Broadridge to $86 and kept his Neutral rating following Q1 results. Heckmann estimates the company's organic revenue growth around 2%-3%, adding that while as much as 80% of its sales are "contractually recurring and fairly predictable", earnings variations are possible due to high-margin equity trade processing and event-driven proxy revenue streams.
08/29/18
RHCO
08/29/18
INITIATION
Target $150
RHCO
Buy
Broadridge initiated with a Buy at SunTrust
SunTrust analyst Oscar Turner initiated Broadridge with a Buy rating and a price target of $150, saying the company will continue to gain "meaningful customer wallet share" and generate long-term mid-single-digit organic revenue growth. Turner adds that the operating leverage of Broadridge suggests "at least" high-single-digit EPS expansion that should be consistent through its current cycle. The analyst believes that the company's "enduring" competitive advantages are derived from " regulatory-driven demand, scale, and few substitute solutions".
MCY Mercury General
$53.21

0.91 (1.74%)

08/28/18
KBWI
08/28/18
INITIATION
Target $64
KBWI
Outperform
Mercury General initiated with an Outperform at Keefe Bruyette
Keefe Bruyette analyst Christopher Campbell initiated Mercury General with an Outperform rating and $64 price target, stating that he expects upside driven by auto rate increases and lower adverse reserve charges.
IMDZ Immune Design
$3.55

0.125 (3.65%)

10/17/17
RBCM
10/17/17
NO CHANGE
Target $23
RBCM
Outperform
Immune Design weakness a buying opportunity, says RBC Capital
RBC Capital said Outperform rated Immune Design's positive FDA feedback on Phase III Trial for CMB305 is a de-risking event. The firm's analyst said the timeline could be pushed back slightly, but improves ultimate POS, while maintaining optionality. RBC recommends buying shares on weakness and raised the price target on shares to $23 from $20 .
10/17/17
WELS
10/17/17
DOWNGRADE
WELS
Market Perform
Immune Design downgraded to Market Perform from Outperform at Wells Fargo
08/29/18
HCWC
08/29/18
INITIATION
Target $11
HCWC
Buy
Immune Design initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis started Immune Design with a Buy rating and $11 price target. The company is engaging the immune system through different avenues and targeting significant unmet medical needs, Pantginis tells investors in a research note. The analyst projects mmune Design could be a leader in the resurgence of cancer vaccines.
09/14/17
RBCM
09/14/17
INITIATION
Target $20
RBCM
Outperform
Immune Design initiated with an Outperform at RBC Capital
RBC Capital analyst Brian Abrahams started Immune Design with an Outperform rating and $20 price target.

TODAY'S FREE FLY STORIES

GIII

G-III Apparel

$28.68

-0.29 (-1.00%)

21:37
12/16/18
12/16
21:37
12/16/18
21:37
Upgrade
G-III Apparel rating change  »

G-III Apparel upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLXT

Calyxt

$9.88

0.4 (4.22%)

21:34
12/16/18
12/16
21:34
12/16/18
21:34
Upgrade
Calyxt rating change  »

Goldman upgrades Calyxt…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLXT

Calyxt

$9.88

0.4 (4.22%)

20:23
12/16/18
12/16
20:23
12/16/18
20:23
Upgrade
Calyxt rating change  »

Calyxt upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CEQP

Crestwood Equity

$32.29

0.47 (1.48%)

, EQM

EQT Midstream Partners

$46.86

-0.1 (-0.21%)

20:08
12/16/18
12/16
20:08
12/16/18
20:08
Recommendations
Crestwood Equity, EQT Midstream Partners analyst commentary  »

Goldman upgrades…

CEQP

Crestwood Equity

$32.29

0.47 (1.48%)

EQM

EQT Midstream Partners

$46.86

-0.1 (-0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ITW

Illinois Tool Works

$131.02

-2.26 (-1.70%)

19:57
12/16/18
12/16
19:57
12/16/18
19:57
Downgrade
Illinois Tool Works rating change  »

Illinois Tool Works…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWK

Stanley Black & Decker

$118.36

0.46 (0.39%)

19:57
12/16/18
12/16
19:57
12/16/18
19:57
Upgrade
Stanley Black & Decker rating change  »

Stanley Black &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INCY

Incyte

$66.24

-1.04 (-1.55%)

, AET

Aetna

$0.00

(0.00%)

19:31
12/16/18
12/16
19:31
12/16/18
19:31
Hot Stocks
Fly Intel: Top five weekend stock stories »

Catch up on the…

INCY

Incyte

$66.24

-1.04 (-1.55%)

AET

Aetna

$0.00

(0.00%)

ANTM

Anthem

$275.59

-4.93 (-1.76%)

CNC

Centene

$127.55

-5.3 (-3.99%)

CI

Cigna

$205.34

-6.63 (-3.13%)

HNT

Health Net

$0.00

(0.00%)

HUM

Humana

$300.41

-12.09 (-3.87%)

MOH

Molina Healthcare

$131.72

-11.19 (-7.83%)

UNH

UnitedHealth

$265.06

-7.2 (-2.64%)

WCG

WellCare

$236.90

-7.44 (-3.04%)

SNE

Sony

$51.32

-0.88 (-1.69%)

GOOG

Alphabet

$1,041.68

-21.44 (-2.02%)

GOOGL

Alphabet Class A

$1,050.62

-23.36 (-2.18%)

AAPL

Apple

$165.48

-5.45 (-3.19%)

BAC

Bank of America

$24.49

0.1 (0.41%)

BLK

BlackRock

$382.25

-5.29 (-1.37%)

CAT

Caterpillar

$126.78

0.79 (0.63%)

CVX

Chevron

$113.84

-2.15 (-1.85%)

DDAIF

Daimler AG

$0.00

(0.00%)

DAL

Delta Air Lines

$53.50

-0.03 (-0.06%)

ET

Energy Transfer LP

$14.08

-0.5 (-3.43%)

TOL

Toll Brothers

$32.23

-0.4 (-1.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

  • 10

    Jan

  • 29

    Jan

  • 05

    Feb

  • 12

    Feb

  • 19

    Feb

  • 24

    Feb

  • 03

    Mar

EQT

EQT Corporation

$19.40

-0.78 (-3.87%)

18:54
12/16/18
12/16
18:54
12/16/18
18:54
Periodicals
EQT's board to seek meeting with Rice brothers, Reuters reports »

EQT Corporation's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQM

EQT Midstream Partners

$46.86

-0.1 (-0.21%)

, EQGP

EQGP Holdings

$19.94

0.02 (0.10%)

18:31
12/16/18
12/16
18:31
12/16/18
18:31
Downgrade
EQT Midstream Partners, EQGP Holdings rating change at Goldman Sachs »

EQT Midstream downgraded…

EQM

EQT Midstream Partners

$46.86

-0.1 (-0.21%)

EQGP

EQGP Holdings

$19.94

0.02 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CEQP

Crestwood Equity

$32.29

0.47 (1.48%)

18:28
12/16/18
12/16
18:28
12/16/18
18:28
Upgrade
Crestwood Equity rating change at Goldman Sachs »

Crestwood Equity upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INCY

Incyte

$66.24

-1.04 (-1.55%)

17:52
12/16/18
12/16
17:52
12/16/18
17:52
Hot Stocks
Innovent, Incyte announce agreement for three clinical-stage candidates in China »

Incyte and Innovent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

NSANY

Nissan

$0.00

(0.00%)

, RNLSY

Renault

$0.00

(0.00%)

17:14
12/16/18
12/16
17:14
12/16/18
17:14
Periodicals
Renault seeking Nissan shareholder meeting amid Ghosn crisis, Reuters says »

Renault (RNLSY) requested…

NSANY

Nissan

$0.00

(0.00%)

RNLSY

Renault

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

T

AT&T

$30.24

0.33 (1.10%)

, CMCSA

Comcast

$36.32

-0.43 (-1.17%)

16:48
12/16/18
12/16
16:48
12/16/18
16:48
Hot Stocks
Box Office Battle: 'Spider-Verse' wins weekend with $35M »

Sony's (SNE)…

T

AT&T

$30.24

0.33 (1.10%)

CMCSA

Comcast

$36.32

-0.43 (-1.17%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$51.32

-0.88 (-1.69%)

FOX

21st Century Fox

$48.79

-0.09 (-0.18%)

FOXA

21st Century Fox

$49.06

-0.07 (-0.14%)

LGF.A

Lionsgate

$15.59

-0.16 (-1.02%)

DIS

Disney

$112.21

-1.17 (-1.03%)

VIAB

Viacom

$28.56

-0.31 (-1.07%)

VIA

Viacom

$31.23

-0.4 (-1.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 30

    Jan

  • 20

    Mar

ELGX

Endologix

$0.71

0.0232 (3.39%)

16:17
12/16/18
12/16
16:17
12/16/18
16:17
Conference/Events
Endologix to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRPO

Precipio

$0.19

-0.0111 (-5.63%)

16:11
12/16/18
12/16
16:11
12/16/18
16:11
Conference/Events
Precipio to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSB

Mesabi Trust

$25.15

-1.1 (-4.19%)

16:08
12/16/18
12/16
16:08
12/16/18
16:08
Conference/Events
Mesabi Trust to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLNT

Melinta Therapeutics

$1.19

-0.1 (-7.75%)

16:02
12/16/18
12/16
16:02
12/16/18
16:02
Conference/Events
Melinta Therapeutics to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XOM

Exxon Mobil

$75.63

-1.32 (-1.72%)

15:55
12/16/18
12/16
15:55
12/16/18
15:55
Periodicals
Exxon Mobil shareholders call for greenhouse gas reduction targets, Reuters says »

A number of institutional…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANTM

Anthem

$275.59

-4.93 (-1.76%)

, CNC

Centene

$127.55

-5.3 (-3.99%)

13:16
12/16/18
12/16
13:16
12/16/18
13:16
Periodicals
Health stocks preparing for market jolt after Obamacare ruling, Bloomberg says »

U.S. health-care stocks…

ANTM

Anthem

$275.59

-4.93 (-1.76%)

CNC

Centene

$127.55

-5.3 (-3.99%)

CI

Cigna

$205.34

-6.63 (-3.13%)

UNH

UnitedHealth

$265.06

-7.2 (-2.64%)

HUM

Humana

$300.41

-12.09 (-3.87%)

WCG

WellCare

$236.90

-7.44 (-3.04%)

MOH

Molina Healthcare

$131.72

-11.19 (-7.83%)

HNT

Health Net

$0.00

(0.00%)

AET

Aetna

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jan

  • 05

    Feb

  • 19

    Feb

JELD

Jeld-Wen

$14.27

-0.46 (-3.12%)

13:02
12/16/18
12/16
13:02
12/16/18
13:02
Hot Stocks
Jeld-Wen announces final ruling in Steves & Sons litigation, to appeal decision »

Jeld-Wen announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATRA

Atara Biotherapeutics

$41.78

-0.74 (-1.74%)

12:55
12/16/18
12/16
12:55
12/16/18
12:55
Hot Stocks
Atara Biotherapeutics presents positive efficacy, safety results for EBV + LMS »

Atara Biotherapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BGNE

BeiGene

$133.95

2.595 (1.98%)

12:41
12/16/18
12/16
12:41
12/16/18
12:41
Hot Stocks
BeiGene announces updated Phase 1A/1B data on tislelizumab »

BeiGene announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JELD

Jeld-Wen

$14.27

-0.46 (-3.12%)

12:35
12/16/18
12/16
12:35
12/16/18
12:35
Hot Stocks
Jeld-Wen ordered to divest Pennsylvania plant to restore competition »

Federal Judge Robert…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMY

Bristol-Myers

$52.11

-1.54 (-2.87%)

, RHHBY

Roche

$0.00

(0.00%)

04:55
12/16/18
12/16
04:55
12/16/18
04:55
Conference/Events
European Society for Medical Oncology (ESMO) to hold a conference »

ESMO Immuno-Oncology…

BMY

Bristol-Myers

$52.11

-1.54 (-2.87%)

RHHBY

Roche

$0.00

(0.00%)

CELG

Celgene

$68.20

-1.55 (-2.22%)

MRK

Merck

$76.50

-1.94 (-2.47%)

PFE

Pfizer

$43.84

-0.71 (-1.59%)

FLDM

Fluidigm

$7.79

-0.39 (-4.77%)

NEO

NeoGenomics

$13.25

-0.18 (-1.34%)

SGEN

Seattle Genetics

$60.46

-0.5 (-0.82%)

TKPYY

Takeda Pharmaceutical

$0.00

(0.00%)

IMV

IMV Inc

$5.65

-0.14 (-2.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

  • 24

    Dec

  • 29

    Dec

  • 11

    Jan

  • 11

    Jan

  • 24

    Jan

  • 16

    Feb

  • 18

    Mar

  • 20

    May

SIR

Select Income REIT

$17.72

-0.52 (-2.85%)

, GOV

Government Properties

$7.68

-0.41 (-5.07%)

17:08
12/15/18
12/15
17:08
12/15/18
17:08
Conference/Events
Select Income REIT to host special shareholder meeting »

Special Shareholder…

SIR

Select Income REIT

$17.72

-0.52 (-2.85%)

GOV

Government Properties

$7.68

-0.41 (-5.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.